Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011 Jun 30;117(26):6977-86.
doi: 10.1182/blood-2010-11-317610. Epub 2011 Apr 12.

High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy

Thomas S Uldrick  1 , Mark N Polizzotto, Karen Aleman, Deirdre O'Mahony, Kathleen M Wyvill, Victoria Wang, Vickie Marshall, Stefania Pittaluga, Seth M Steinberg, Giovanna Tosato, Denise Whitby, Richard F Little, Robert Yarchoan
Affiliations
Clinical Trial

High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy

Thomas S Uldrick et al. Blood. .

Abstract

Kaposi sarcoma herpesvirus (KSHV)-associated multicentric Castleman disease (MCD) is a lymphoproliferative disorder most commonly observed in HIV-infected patients. It is characterized by KSHV-infected plasmablasts that frequently express lytic genes. Patients manifest inflammatory symptoms attributed to overproduction of KSHV viral IL-6, human IL-6, and human IL-6. There is no standard therapy and no established response criteria. We investigated an approach targeting 2 KSHV lytic genes, ORF36 and ORF21, the protein of which, respectively, phosphorylate ganciclovir and zidovudine to toxic moieties. In a pilot study, 14 HIV-infected patients with symptomatic KSHV-MCD received high-dose zidovudine (600 mg orally every 6 hours) and the oral prodrug, valganciclovir (900 mg orally every 12 hours). Responses were evaluated using new response criteria. A total of 86% of patients attained major clinical responses and 50% attained major biochemical responses. Median progression-free survival was 6 months. With 43 months of median follow-up, overall survival was 86% at 12 months and beyond. At the time of best response, the patients showed significant improvements in C-reactive protein, albumin, platelets, human IL-6, IL-10, and KSHV viral load. The most common toxicities were hematologic. These observations provide evidence that therapy designed to target cells with lytic KSHV replication has activity in KSHV-MCD. This trial was registered at www.clinicaltrials.gov as #NCT00099073.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Best radiographic responses. (A) Percentage change in sum of the products of 6 representational lymph nodes at time of best radiographic response compared with baseline, in the 11 patients with pathologic lymphadenopathy at baseline evaluable. Patients can have a radiographic complete response with < 100% decrease in sum of the products of representational lymph nodes as long as there is no pathologic adenopathy at time of evaluation. (B) Percentage change in longest dimension of spleen size (normalized to spleen upper limit of normal = 12 cm) at time of best radiographic response compared with baseline, 10 patients with splenomegaly at baseline evaluable, maximum normalization = 100%.
Figure 2
Figure 2
Kaplan-Meier survival function. (A) Progression-free survival. (B) Overall survival. Hatch marks represent time subjects censored.
Figure 3
Figure 3
Changes in C-reactive protein and viral IL-6 in patients with symptomatic KSHV-MCD from baseline to time of best clinical response. Wilcoxon matched-pair signed-rank test comparing changes from baseline laboratories to a time point of best clinical response is performed on all evaluable patients (14 patients evaluable for CRP, 12 patients evaluable for vIL-6) and then repeated with exclusion of 1 patient whose assessment was confounded by development endocarditis *(■----■) in (A) C-reactive protein (mg/dL), (P = .0085, *P = .0002) and (B) vIL-6 (pg/mL; not significant). In 6 patients, vIL-6 was undetectable both at baseline and time of best clinical response.
See this image and copyright information in PMC

Comment in

  • KSHV: forgotten but not gone.
    Moore PS, Chang Y. Moore PS, et al. Blood. 2011 Jun 30;117(26):6973-4. doi: 10.1182/blood-2011-05-350306. Blood. 2011. PMID: 21719604 No abstract available.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61–67. - PubMed
    1. Waterston A, Bower M. Fifty years of multicentric Castleman's disease. Acta Oncol. 2004;43(8):698–704. - PubMed
    1. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865–1869. - PubMed
    1. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276–1280. - PubMed
    1. Teruya-Feldstein J, Zauber P, Setsuda JE, et al. Expression of human herpesvirus-8 oncogene and cytokine homologues in an HIV-seronegative patient with multicentric Castleman's disease and primary effusion lymphoma. Lab Invest. 1998;78(12):1637–1642. - PubMed

Publication types

MeSH terms

Supplementary concepts

Associated data